AI Licensing
Somebody asked me this week what I thought about AMA and NEJM licensing to Open Evidence and earlier, Wolters Kluwer and LexisNexis to…
Somebody asked me this week what I thought about AMA and NEJM licensing to Open Evidence and earlier, Wolters Kluwer and LexisNexis to…
Excited to share plans for October 8 in London where we are hosting select CEOs, COOs, MDs, & Presidents by-invitation for a meeting one…
Outsell clients have the benefit of a feature we call ‘inquiry privilege.’ It’s the ability to ask questions (in confidence) about thorny…
It was a matter of time. Not months or years. Nanosecond time. We see it when big boulders start to roll downhill. They move gradually…
It’s another week when someone predicts the big tear-down. This time, it’s BigTech vs. BigFour.
It starts with LinkedIn and someone boasting about AI and its replacement of something big, bold, popular — in this case the Bloomberg…
I received this note from a Thomson Reuters sales rep and so did another colleague who is no longer with our company. The whole thing…
Copyright continues to be under fire. Our colleagues Hugh Logue and Tatiana Khayrullina wrote about the impact of two recent rulings; one…
It’s been a rough week for tradition. First, after 148 years the Wimbledon line judge is no more; the game will now rely on Hawk-Eye…
When news of OpenAI’s ChatGPT broke, which now feels like a decade ago, we made that year’s meta-theme AI Everywhere All at Once.